Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA (R) (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP.

Next Previous
Search
Trial Profile

Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA (R) (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 02 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
  • 02 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 04 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top